Facebook Twitter RSS Feed

You are here

Nuclear Cardiology

 - AT1R Uptake

Molecular imaging is beginning to give cardiologists insight into biological processes behind heart failure, knowledge that may allow them to monitor disease progression and tailor therapies. But market realities still pose barriers.

 - heart puzzle

FluoroPharma Medical, based in Montclair, N.J., announced yesterday that new results from an ongoing phase II clinical trial for F-18 FCPHA cardiac PET for the diagnosis of acute coronary artery disease (CAD) were positive and providing validation for further research.

 - Neon Heart

The rubidium-ARMI (alternative radiopharmaceutical for myocardial imaging) multicenter trial has established a bar for assessing myocardial perfusion imaging (MPI) that meets or even exceeds previous SPECT MPI reader scores after thorough consensus review, according to a study published Nov. 18 in the Journal of Nuclear Medicine.

 - Neon Heart

FDG uptake rose substantially in PET/CT scans of patients with higher levels of C-reative protein in their carotid arteries, pinpointing a potential biomarker for cardiovascular disease, according to an article published online Oct. 31 in the Journal of Nuclear Medicine.

 

More Stories

Other side of the coin: CT has advantages over SPECT for detection of stable CAD

In a companion piece that counters an opinion that SPECT is the best modality for first-line detection of CAD, separate experts argued that CT finds sub-clinical atherosclerosis and important coronary anatomy, providing earlier diagnoses and the option to be more aggressive with treatment, according to a review published April 10 in the Journal of Nuclear Cardiology.

SPECT beats CT for detection of stable CAD

Some clinicians maintain that cardiac-computed tomography angiography (CCTA) bests SPECT/CT for the detection of CAD, but two expert nuclear cardiologists suggest the opposite and presented data to demonstrate their case, in a study published April 10 in the Journal of Nuclear Cardiology.

In a heartbeat: Cardiac FDG PET/MR effective, beneficial for ischemia

Simultaneous PET/MR broke additional ground toward clinical use by showing technical success and potential clinical merit for FDG PET/MR detection of ischemic heart disease, according to a study published May 7 in Radiology.

The power of exercise: SPECT MPI in active patients may be unnecessary

Many older patients undergoing an exercise stress test may not need molecular imaging to provide a clear picture of cardiovascular health. Evidence suggests that SPECT MPI may not provide any additional information for those who are nimble enough to reach a certain level of exertion and show no signs of CAD or cardiovascular distress. These and similar findings point to potential radioisotope injection guidelines to reduce radiation dose and cost of healthcare for these patients, according to research presented at the International Conference on Nuclear Cardiology and Cardiac CT, held May 5 to 8 in Berlin.

Add it up: Quantifying myocardial perfusion reserve w/ SPECT viable

Researchers are developing a method of quantitative myocardial perfusion imaging that analyzes myocardial perfusion reserve using SPECT with advanced cadmium zinc telluride crystal detectors to unlock extent of coronary artery disease, according to a study published April 11 by The Journal of Nuclear Medicine.

CZT SPECT accurately quantifies ejection fraction

While myocardial perfusion imaging using cadmium-zinc-telluride (CZT) SPECT cameras accurately measures left ventricular ejection fraction, the method underestimates left ventricular volumes, according to a study published online Feb. 5 in the Journal of Nuclear Medicine.

Positron subsidiary nets FDA drug master file for Sr-82

Positron's subsidiary, Manhattan Isotope Technology, has received an acknowledgment letter and Drug Master File number assignment from the FDA for its strontium-82 drug substance.